MILANI, RODOLFO
 Distribuzione geografica
Continente #
NA - Nord America 10.442
AS - Asia 5.039
EU - Europa 4.042
SA - Sud America 705
AF - Africa 132
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 13
Totale 20.391
Nazione #
US - Stati Uniti d'America 9.962
SG - Singapore 1.790
CN - Cina 1.218
HK - Hong Kong 688
RU - Federazione Russa 639
VN - Vietnam 597
BR - Brasile 535
DE - Germania 517
SE - Svezia 510
IT - Italia 508
UA - Ucraina 495
IE - Irlanda 452
CA - Canada 402
GB - Regno Unito 271
FR - Francia 197
IN - India 177
FI - Finlandia 129
BD - Bangladesh 93
TR - Turchia 69
AT - Austria 58
IQ - Iraq 57
ZA - Sudafrica 53
NL - Olanda 51
MX - Messico 47
AR - Argentina 45
KR - Corea 45
PH - Filippine 44
ES - Italia 42
DK - Danimarca 41
JP - Giappone 39
SA - Arabia Saudita 38
EC - Ecuador 33
BE - Belgio 32
PL - Polonia 31
CO - Colombia 29
ID - Indonesia 28
PK - Pakistan 25
VE - Venezuela 20
UZ - Uzbekistan 18
MA - Marocco 17
PY - Paraguay 16
EU - Europa 14
MY - Malesia 14
TN - Tunisia 14
CH - Svizzera 13
CZ - Repubblica Ceca 12
IL - Israele 10
KE - Kenya 10
TH - Thailandia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
PE - Perù 9
IR - Iran 8
JM - Giamaica 8
KZ - Kazakistan 8
AU - Australia 7
EG - Egitto 7
ET - Etiopia 7
JO - Giordania 7
OM - Oman 7
PT - Portogallo 7
AL - Albania 6
CR - Costa Rica 6
GR - Grecia 5
NP - Nepal 5
RS - Serbia 5
AM - Armenia 4
AZ - Azerbaigian 4
DZ - Algeria 4
HU - Ungheria 4
LB - Libano 4
LT - Lituania 4
LV - Lettonia 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
GY - Guiana 3
KW - Kuwait 3
PS - Palestinian Territory 3
QA - Qatar 3
SN - Senegal 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UY - Uruguay 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
GE - Georgia 2
HN - Honduras 2
KH - Cambogia 2
LK - Sri Lanka 2
LY - Libia 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
RO - Romania 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
Totale 20.365
Città #
Ann Arbor 1.143
Singapore 1.040
Ashburn 893
Woodbridge 847
Hong Kong 660
Fairfield 643
Houston 615
San Jose 587
Chandler 545
Jacksonville 503
Dublin 425
Dearborn 328
Frankfurt am Main 291
Wilmington 285
New York 263
Seattle 241
Toronto 240
Cambridge 234
Beijing 207
Princeton 194
Ho Chi Minh City 182
Los Angeles 143
The Dalles 140
Hanoi 139
Chicago 138
Nanjing 133
Santa Clara 125
Hefei 101
Milan 101
Dallas 96
Shanghai 90
Lachine 88
Lawrence 87
Boardman 86
Altamura 85
Lauterbourg 80
Council Bluffs 72
Moscow 69
Buffalo 59
Lissone 58
Vienna 55
São Paulo 53
Nanchang 45
London 41
Da Nang 38
San Diego 35
Seoul 34
Brussels 32
Shenyang 32
Guangzhou 31
Ottawa 31
Huizen 30
Andover 29
Munich 28
Changsha 27
Haiphong 27
Orem 27
Tokyo 26
Rome 25
Washington 25
Jiaxing 24
Helsinki 23
Baghdad 22
Johannesburg 22
Hebei 21
Falls Church 19
Jinan 19
Kunming 19
Chennai 18
Tianjin 18
Warsaw 18
Atlanta 17
Boston 17
Denver 17
Tashkent 17
Turku 17
Manchester 16
Rio de Janeiro 16
Riyadh 16
Stockholm 16
Brooklyn 15
Fremont 15
Norwalk 15
Dhaka 14
Guayaquil 14
Montreal 14
Phoenix 14
Mountain View 13
Belo Horizonte 12
Mexico 12
Mumbai 12
Tampa 12
Brasília 11
City of London 11
Curitiba 11
New Delhi 10
Amsterdam 9
Biên Hòa 9
Düsseldorf 9
Nuremberg 9
Totale 13.540
Nome #
Stem cell augmented mesh materials: an in vitro and in vivo study 422
Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping 393
Three-dimensional ultrasound assessment and middle term efficacy of a single-incision sling 382
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 381
Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer 99mTc and/or Blue Dye 362
Histologic and metabolic assessment in a cohort of patients with genital prolapse: Preoperative stage and recurrence investigations 357
Iliococcygeus fixation or abdominal sacral colpopexy for the treatment of vaginal vault prolapse: a retrospective cohort study 350
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 345
Incidence and risk factors of third- and fourth-degree perineal tears in a single Italian scenario 344
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 338
Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease? 332
Risk factors for persistent, de novo and overall overactive bladder syndrome after surgical prolapse repair 324
Better anatomical and cosmetic results using tunneled lotus petal flap for plastic reconstruction after demolitive surgery for vulvar malignancyc 318
Integration of hybrid single-photon emission computed tomography/computed tomography in the preoperative assessment of sentinel node in patients with cervical and endometrial cancer: Our experience and literature review 315
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer 315
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 314
Transvaginal primary repair of a suprasphincteric rectovaginal fistula 314
The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: A double institution observational study 311
Optimizing strategies for sentinel lymph node mapping in early-stage cervical and endometrial cancer: Comparison of real-time fluorescence with indocyanine green and methylene blue 305
Sentinel Lymph Node Mapping With Near-Infrared Fluorescent Imaging Using Indocyanine Green: A New Tool for Laparoscopic Platform in Patients With Endometrial and Cervical Cancer 298
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 293
Near-Infrared Sentinel Lymph Node Mapping With Indocyanine Green Using the VITOM II ICG Exoscope for Open Surgery for Gynecologic Malignancies 293
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 284
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: A prospective randomized study 281
The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy 272
Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial 262
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 261
Primary insular carcinoid of the ovary with carcinoid heart disease: Unfavourable outcome of a case 256
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 255
Maximum standardized uptake value (SUVmax) as prognostic factor for surgical cytoreduction and response to adjuvant chemotherapy in women submitted to 18F-FDG PET/CT for staging of advanced epithelial ovarian cancer (aEOC) 255
The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy 250
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 250
Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: A series of nine cases and literature review 248
Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA 247
Piperacillin versus cefotetan as single-dose prophylaxis in abdominal hysterectomy: A prospective, randomized, multicenter study 242
Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations 235
Prevention of postoperative urinary stress incontinence after surgery for genitourinary prolapse 233
DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer 225
Comparison of flavoxate hydrochloride in daily dosages of 600 versus 1200 mg for the treatment of urgency and urge incontinence 221
Sulbactam/ampicillin versus cefotetan in the treatment of obstetric and gynecologic infections 220
Burch colposuspension versus modified Marshall-Marchetti-Krantz urethropexy for primary genuine stress urinary incontinence: a prospective, randomized clinical trial 220
Chromocystoscopy in the urological monitoring of patients with cancer of the cervix 215
Systematic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgery and chemotherapy: a retrospective study 215
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer 214
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities 214
Topical fenticonazole in dermatology and gynaecology: current role in therapy 212
Tumor volume calculation with VOCAL software in endometrial cancer patients: a reproducibility study 209
A randomized comparison of continuous versus interrupted mass closure of midline incisions in patients with gynecologic cancer 204
Flavoxate hydrochloride for urinary urgency after pelvic radiotherapy: comparison of 600 mg versus 1200 mg daily dosages 202
Clinical evaluation of piperacillin in the treatment of severe infections in obstetrics and gynecology 199
Double incontinence in urogynecologic practice: a new insight 192
Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review 189
Randomized study between radical surgery and radiotherapy for the treatment of stage IB–IIA cervical cancer: 20-year update 188
Embryo transfer following in vitro maturation and cryopreservation of oocytes recovered from antral follicles during conservative surgery for ovarian cancer 185
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 184
The relationship of urethral resistance pressure and pressure flow parameters in women with lower urinary tract symptoms 181
Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy 181
A double-blind trial of fentonium bromide in the treatment of incontinent unstable bladder 181
Surgery for genitourinary prolapse and stress incontinence: a randomized trial of posterior pubourethral ligament plication and Pereyra suspension 179
Repair of the Perineal Defect After Radical Vulvar Surgery: Direct Closure Versus Skin Flaps Reconstruction: A Retrospective Comparative Study 179
Pefloxacin in the treatment of severe infections in gynecological cancer patients 179
Reply to: Are the outcomes of neoadjuvant chemotherapy for stage Ib2 cervical cancer similar in pregnant and nonpregnant patients? 178
Sentinel node mapping in high risk endometrial cancer after laparoscopic supracervical hysterectomy with morcellation 178
Early diagnosis and prevention of female genital neoplasms in a clinic: preliminary evaluations 176
Marshall-Marchetti-Krantz procedure and Burch colposuspension in the surgical treatment of female urinary incontinence 176
Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial 172
Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients 166
Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study 164
Significance of biopsy of the female vesical trigone 162
Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy 162
Identification of risk factors for genital prolapse recurrence 161
Cystometric evaluation of bladder function after radical hysterectomy 161
Functional and anatomical outcome of anterior and posterior vaginal prolapse repair with prolene mesh 159
Vulvar endometriosis in surgical scar after excision of the Bartholin gland: report of a case 159
Early and late pathology of the urinary tract after radical hysterectomy 158
Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study 158
Anatomo-functional results of surgical repair of the urological complications following radiotherapy, surgery or combined therapy of cervical carcinoma 156
Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity 153
Patterns of constipation in urogynecology: clinical importance and pathophysiologic insights 151
Hospital infections in obstetrics and gynecology 151
Urinary stress incontinence treatment with Remeex in a patient with epispadias: a case report 150
International Continence Society - 32nd Annual Meeting - Heidelberg, Germany - 28-30 August 2002 - Abstracts 147
Anomalie delle strutture di supporto della pelvi 145
Major and minor urological complications after simple hysterectomy for malignant tumors of the female genital system 145
Pressure flow study: a useful diagnostic test of female lower urinary tract symptoms 145
Ulipristal acetate versus leuprolide acetate for uterine fibroids 144
Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse? 134
A case of laparoscopic uterosacral ligaments plication: a new conservative approach to uterine prolapse? 129
Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives 127
Spontaneous uterine rupture in the third trimester of gestation after laparoscopic myomectomy. A case report 125
Anatomia funzionale del basso tratto urinario 123
Totale 20.640
Categoria #
all - tutte 68.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.549


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202150 0 0 0 0 0 0 0 0 0 0 0 50
2021/2022868 40 74 71 62 78 66 40 67 44 82 61 183
2022/20231.920 192 612 143 199 144 328 10 93 143 15 27 14
2023/20241.233 27 40 50 60 178 347 289 22 80 15 7 118
2024/20252.466 153 285 100 123 201 60 107 163 227 403 209 435
2025/20267.037 668 407 495 758 891 390 1.225 375 644 654 386 144
Totale 20.640